Our Take
Liaison officers are a procedural upgrade, not a regulatory rethink—expect incremental alignment on case-by-case basics, not harmonized standards that eliminate duplicate review.
Why it matters
Companies seeking dual approval in the US and UK face duplicative review cycles and divergent requirements. Closer FDA-MHRA coordination could compress timelines, but only if the liaison structure moves beyond knowledge-sharing into active decision-alignment.
Do this week
Regulatory affairs: map your current FDA and MHRA submission timelines now, before liaison officers are staffed, to establish a baseline for measuring whether dual-track review actually accelerates.
Two regulators formalize collaboration with reciprocal liaison roles
The US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) announced a formal liaison programme at the DIA Global Annual Meeting in Philadelphia on June 14–18. The initiative centers on three areas: medical devices, artificial intelligence, and innovative medicines.
The core mechanism is the appointment of reciprocal liaison officers embedded within each agency. These roles are designed to enhance day-to-day collaboration, support scientific exchange, and streamline responses to emerging regulatory challenges. Both agencies stated the programme will maintain full regulatory independence while improving alignment on how they handle advances in science and technology.
MHRA CEO Lawrence Tallon framed the liaison structure as a way to reduce market friction for companies seeking approval in both jurisdictions. "Our regulatory decisions will become more closely aligned, reducing friction to market from the UK to the US and vice versa," Tallon said. FDA deputy commissioner Grace Graham emphasized the patient benefit: aligning on regulatory science "can speed access to medical products and reduce time to markets both here and in the UK."
The announcement follows an April commitment by both agencies to deepen cooperation on medical device regulation and comes as the MHRA finalizes a new AI regulatory framework. In a MHRA consultation on AI regulation that closed June 11, 761 stakeholders responded; 50% said the existing framework needed substantial revision, and 21% called for complete overhaul (per the MHRA policy document).
Regulatory alignment reduces but does not eliminate duplicate review
Companies developing medical devices, diagnostics, or AI-enabled tools for healthcare must currently navigate separate submission pathways, timelines, and evidentiary standards in the US and UK. The liaison programme addresses a real friction point: regulators working in parallel rather than in sequence means redundant reviews and conflicting feedback.
However, liaison officers function as communication channels, not arbiters of divergent standards. The agencies retain independent authority to approve or reject products. Meaningful acceleration depends on whether liaison officers can pre-align on key scientific questions (e.g., what evidence supports an AI algorithm's safety) before formal submissions begin, or whether they remain conduits for information after the fact.
The timing intersects with two other regulatory moves. The UK-US pharmaceutical trade agreement (implemented April 2026) set 0% tariffs on UK drug exports to the US, with the NHS raising net prices on new branded medicines by 25% in return. The MHRA's incoming AI framework will replace current medical device regulation (MDR) governance of healthcare AI. If the liaison programme influences how that new framework interoperates with FDA guidance, the impact could be material. If it is advisory only, impact will be marginal.
Industry groups have already signaled appetite. Scott Whitaker, CEO of the Advanced Medical Technology Association (AdvaMed), stated closer alignment will "accelerate patient access to lifesaving medtech on both sides of the Atlantic." Duncan Edwards, CEO of BritishAmerican Business, called it a positive signal for investment certainty.
Regulatory teams should baseline current timelines and audit submission differences now
The liaison programme is staffing-dependent and its operational tempo is unknown. Regulatory affairs leaders should document the current dual-submission process: file dates, decision timelines, information requests, and divergences in accepted evidence for device types and therapeutic areas your organization uses. This baseline will show whether liaison officers actually compress review cycles or merely improve communication without changing the underlying sequential or parallel review structure.
Audit your current AI/device submissions for redundant data requests across jurisdictions. If liaison officers begin pre-alignment activities, they will likely target the highest-friction categories first. Organizations that can articulate which decisions generate duplicate work will be positioned to feed that intelligence to liaison staff and potentially influence early collaboration patterns.
Do not assume this programme eliminates the need for separate regulatory counsel in each jurisdiction. Liaison officers work within existing agency mandates. Full regulatory independence remains, meaning divergence in final decisions remains possible. Treat this as a communication upgrade, not a standards merger.